77 related articles for article (PubMed ID: 35626126)
1. Clinical impact of heterogeneously distributed tumor-infiltrating lymphocytes on the prognosis of colorectal cancer.
Liu L; Long M; Su S; Wang L; Liu J
PeerJ; 2024; 12():e16747. PubMed ID: 38223758
[TBL] [Abstract][Full Text] [Related]
2. Immunochemistry-based quantification of tumor-infiltrating lymphocytes and immunoscore as prognostic biomarkers in bladder cancer.
Rejeb SB; Elfekih S; Kouki N; Boulma R; Khouni H
J Egypt Natl Canc Inst; 2024 Mar; 36(1):9. PubMed ID: 38523233
[TBL] [Abstract][Full Text] [Related]
3. TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes.
Würfel F; Erber R; Huebner H; Hein A; Lux MP; Jud S; Kremer A; Kranich H; Mackensen A; Häberle L; Hack CC; Rauh C; Wunderle M; Gaß P; Rabizadeh S; Brandl AL; Langemann H; Volz B; Nabieva N; Schulz-Wendtland R; Dudziak D; Beckmann MW; Hartmann A; Fasching PA; Rübner M
Breast Care (Basel); 2018 Mar; 13(1):8-14. PubMed ID: 29950961
[TBL] [Abstract][Full Text] [Related]
4. Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients.
Wang Y; Dong J; Quan Q; Liu S; Chen X; Cai X; Qiu H; Zhang B; Guo G
Front Oncol; 2020; 10():581051. PubMed ID: 33585196
[TBL] [Abstract][Full Text] [Related]
5. Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer.
Cerbelli B; Scagnoli S; Mezi S; De Luca A; Pisegna S; Amabile MI; Roberto M; Fortunato L; Costarelli L; Pernazza A; Strigari L; Della Rocca C; Marchetti P; d'Amati G; Botticelli A
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32947953
[TBL] [Abstract][Full Text] [Related]
6. Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers.
Tseng LM; Huang CC; Tsai YF; Chen JL; Chao TC; Lai JI; Lien PJ; Lin YS; Feng CJ; Chen YJ; Chiu JH; Hsu CY; Liu CY
Transl Oncol; 2023 Dec; 38():101782. PubMed ID: 37713974
[TBL] [Abstract][Full Text] [Related]
7. Towards tumor immunodiagnostics.
Kourea H; Kotoula V
Ann Transl Med; 2016 Jul; 4(14):263. PubMed ID: 27563650
[TBL] [Abstract][Full Text] [Related]
8. A dataset of tumour-infiltrating lymphocytes in colorectal cancer patients using limited resources.
Hasnaoui A; Helal I; Ben Azouz Z; Hmidi A; Jouini R; Chadli-Debbiche A
Database (Oxford); 2023 Dec; 2023():0. PubMed ID: 38104276
[TBL] [Abstract][Full Text] [Related]
9. Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer.
Fisher TB; Saini G; Rekha TS; Krishnamurthy J; Bhattarai S; Callagy G; Webber M; Janssen EAM; Kong J; Aneja R
Breast Cancer Res; 2024 Jan; 26(1):12. PubMed ID: 38238771
[TBL] [Abstract][Full Text] [Related]
10. Predicting Neoadjuvant Treatment Response in Triple-Negative Breast Cancer Using Machine Learning.
Bhattarai S; Saini G; Li H; Seth G; Fisher TB; Janssen EAM; Kiraz U; Kong J; Aneja R
Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201383
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of immune density, PD-L1, and CXCR4 expressions in metaplastic breast carcinoma to predict potential immunotherapy benefit.
Bagbudar S; Karanlık H; Cabioglu N; Bayram A; Tükenmez M; Aydıner A; Yavuz E; Onder S
Med Oncol; 2023 Dec; 41(1):18. PubMed ID: 38102446
[TBL] [Abstract][Full Text] [Related]
12. Diagnostics and Therapeutics in Early Stage Breast Cancer Receiving Neoadjuvant Systemic Therapy.
Belli P; Palma S; Costantini M
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835568
[TBL] [Abstract][Full Text] [Related]
13. Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods.
Porta FM; Sajjadi E; Venetis K; Frascarelli C; Cursano G; Guerini-Rocco E; Fusco N; Ivanova M
J Pers Med; 2023 Jul; 13(7):. PubMed ID: 37511789
[TBL] [Abstract][Full Text] [Related]
14. Opportunities and challenges to engineer 3D models of tumor-adaptive immune interactions.
Visalakshan RM; Lowrey MK; Sousa MGC; Helms HR; Samiea A; Schutt CE; Moreau JM; Bertassoni LE
Front Immunol; 2023; 14():1162905. PubMed ID: 37081897
[TBL] [Abstract][Full Text] [Related]
15. Exosomal Plasma Gelsolin Is an Immunosuppressive Mediator in the Ovarian Tumor Microenvironment and a Determinant of Chemoresistance.
Onuma T; Asare-Werehene M; Yoshida Y; Tsang BK
Cells; 2022 Oct; 11(20):. PubMed ID: 36291171
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3
Rapoport BL; Nayler S; Mlecnik B; Smit T; Heyman L; Bouquet I; Martel M; Galon J; Benn CA; Anderson R
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626126
[TBL] [Abstract][Full Text] [Related]
17. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of various immune cells and Immunoscore in triple-negative breast cancer.
Ren X; Song Y; Pang J; Chen L; Zhou L; Liang Z; Wu H
Front Immunol; 2023; 14():1137561. PubMed ID: 37090736
[TBL] [Abstract][Full Text] [Related]
19. Density and location of CD3
Zhou C; Wu Y; Jiang L; Li Z; Diao P; Wang D; Zhang W; Liu L; Wang Y; Jiang H; Cheng J; Yang J
J Oral Pathol Med; 2018 Apr; 47(4):359-367. PubMed ID: 29469989
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
